Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification
In 2010, World Health Organization classified gastric neuroendocrine tumor (NET) as follows: NET grade (G) 1, NET G2, neuroendocrine carcinoma (NEC). We reviewed 22 gastric NETs that were encountered in our institutions. Nine, 6, and 4 were NET G1, G2, and NEC, respectively. We also encountered 3 NE...
Gespeichert in:
| Veröffentlicht in: | International surgery 2012-10, Vol.97 (4), p.335-339 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 4 |
| container_start_page | 335 |
| container_title | International surgery |
| container_volume | 97 |
| creator | Endo, Shunji Dousei, Tsutomu Yoshikawa, Yukinobu Hatanaka, Nobutaka Taniyama, Kiyomi Yamauchi, Amane Kamiike, Wataru Nishijima, Junichi |
| description | In 2010, World Health Organization classified gastric neuroendocrine tumor (NET) as follows: NET grade (G) 1, NET G2, neuroendocrine carcinoma (NEC). We reviewed 22 gastric NETs that were encountered in our institutions. Nine, 6, and 4 were NET G1, G2, and NEC, respectively. We also encountered 3 NET G3. NET G1 was treated with observation in 2 patients, endoscopic mucosal resection (EMR) in 3, and gastrectomy in 4 patients. No recurrence was experienced during a median of 53 months of follow-up. All NET G2 was treated with gastrectomy. No patient experienced recurrence during a median of 25 months of follow-up. NET G3 was treated with gastrectomy. One patient died of liver metastasis 52 months after gastrectomy. For NEC, gastrectomy was performed in 3 cases and no patients died of tumor-related death. We conclude that the prognoses of NET G1 and G2 were good. We also experienced long-term survivors of NEC. An accumulation of more patients is needed for further investigation. |
| doi_str_mv | 10.9738/cc134.1 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3727259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>23294075</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-20b344281eb278f297e89060e2c9d3b9abbcb2482756b2876d3f68695b7bc0753</originalsourceid><addsrcrecordid>eNpVkEFLAzEQhYMotlbxH0hunrZmJ7ub5CLIoq1Q6EURvIQkm20j7aYkWcF_75Zq0dMbmG_e8B5C1zmZCkb5nTE5Lab5CRpDCSSDoqxO0ZiQYea84iN0EeMHIVTQUpyjEVAQBWHlGL3PVEzBGdzZPnjbNd4E11mc-q0PEbsO-z4MEpNLfXK-i1gZ40PjuhVOHqe1xW_zJQaSE2w2KkbXOqP25CU6a9Um2qsfnaDXp8eXep4tlrPn-mGRmYLRlAHRtCiA51YD4y0IZrkgFbFgREO1UFobDQUHVlYaOKsa2la8EqVm2gwZ6ATdH3x3vd7axtguBbWRu-C2KnxJr5z8v-ncWq78p6QMGJRiMLg9GJjgYwy2Pd7mRO7rlXU91Cvzgbz5--rI_fZJvwGdvHZY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Endo, Shunji ; Dousei, Tsutomu ; Yoshikawa, Yukinobu ; Hatanaka, Nobutaka ; Taniyama, Kiyomi ; Yamauchi, Amane ; Kamiike, Wataru ; Nishijima, Junichi</creator><creatorcontrib>Endo, Shunji ; Dousei, Tsutomu ; Yoshikawa, Yukinobu ; Hatanaka, Nobutaka ; Taniyama, Kiyomi ; Yamauchi, Amane ; Kamiike, Wataru ; Nishijima, Junichi</creatorcontrib><description>In 2010, World Health Organization classified gastric neuroendocrine tumor (NET) as follows: NET grade (G) 1, NET G2, neuroendocrine carcinoma (NEC). We reviewed 22 gastric NETs that were encountered in our institutions. Nine, 6, and 4 were NET G1, G2, and NEC, respectively. We also encountered 3 NET G3. NET G1 was treated with observation in 2 patients, endoscopic mucosal resection (EMR) in 3, and gastrectomy in 4 patients. No recurrence was experienced during a median of 53 months of follow-up. All NET G2 was treated with gastrectomy. No patient experienced recurrence during a median of 25 months of follow-up. NET G3 was treated with gastrectomy. One patient died of liver metastasis 52 months after gastrectomy. For NEC, gastrectomy was performed in 3 cases and no patients died of tumor-related death. We conclude that the prognoses of NET G1 and G2 were good. We also experienced long-term survivors of NEC. An accumulation of more patients is needed for further investigation.</description><identifier>ISSN: 0020-8868</identifier><identifier>EISSN: 2520-2456</identifier><identifier>DOI: 10.9738/cc134.1</identifier><identifier>PMID: 23294075</identifier><language>eng</language><publisher>Italy: International College of Surgeons</publisher><subject>Aged ; Carcinoma, Neuroendocrine - classification ; Carcinoma, Neuroendocrine - pathology ; Carcinoma, Neuroendocrine - surgery ; Female ; Follow-Up Studies ; Gastrectomy ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neuroendocrine Tumors - classification ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - surgery ; Neuroendocrine Tumors - therapy ; Retrospective Studies ; Stomach Neoplasms - classification ; Stomach Neoplasms - pathology ; Stomach Neoplasms - surgery ; Stomach Neoplasms - therapy ; Treatment Outcome ; Upper Gastrointestinal Surgery ; Watchful Waiting ; World Health Organization</subject><ispartof>International surgery, 2012-10, Vol.97 (4), p.335-339</ispartof><rights>Copyright 2012 by the International College of Surgeons 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-20b344281eb278f297e89060e2c9d3b9abbcb2482756b2876d3f68695b7bc0753</citedby><cites>FETCH-LOGICAL-c473t-20b344281eb278f297e89060e2c9d3b9abbcb2482756b2876d3f68695b7bc0753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727259/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727259/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23294075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Endo, Shunji</creatorcontrib><creatorcontrib>Dousei, Tsutomu</creatorcontrib><creatorcontrib>Yoshikawa, Yukinobu</creatorcontrib><creatorcontrib>Hatanaka, Nobutaka</creatorcontrib><creatorcontrib>Taniyama, Kiyomi</creatorcontrib><creatorcontrib>Yamauchi, Amane</creatorcontrib><creatorcontrib>Kamiike, Wataru</creatorcontrib><creatorcontrib>Nishijima, Junichi</creatorcontrib><title>Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification</title><title>International surgery</title><addtitle>Int Surg</addtitle><description>In 2010, World Health Organization classified gastric neuroendocrine tumor (NET) as follows: NET grade (G) 1, NET G2, neuroendocrine carcinoma (NEC). We reviewed 22 gastric NETs that were encountered in our institutions. Nine, 6, and 4 were NET G1, G2, and NEC, respectively. We also encountered 3 NET G3. NET G1 was treated with observation in 2 patients, endoscopic mucosal resection (EMR) in 3, and gastrectomy in 4 patients. No recurrence was experienced during a median of 53 months of follow-up. All NET G2 was treated with gastrectomy. No patient experienced recurrence during a median of 25 months of follow-up. NET G3 was treated with gastrectomy. One patient died of liver metastasis 52 months after gastrectomy. For NEC, gastrectomy was performed in 3 cases and no patients died of tumor-related death. We conclude that the prognoses of NET G1 and G2 were good. We also experienced long-term survivors of NEC. An accumulation of more patients is needed for further investigation.</description><subject>Aged</subject><subject>Carcinoma, Neuroendocrine - classification</subject><subject>Carcinoma, Neuroendocrine - pathology</subject><subject>Carcinoma, Neuroendocrine - surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastrectomy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neuroendocrine Tumors - classification</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Neuroendocrine Tumors - surgery</subject><subject>Neuroendocrine Tumors - therapy</subject><subject>Retrospective Studies</subject><subject>Stomach Neoplasms - classification</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - surgery</subject><subject>Stomach Neoplasms - therapy</subject><subject>Treatment Outcome</subject><subject>Upper Gastrointestinal Surgery</subject><subject>Watchful Waiting</subject><subject>World Health Organization</subject><issn>0020-8868</issn><issn>2520-2456</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkEFLAzEQhYMotlbxH0hunrZmJ7ub5CLIoq1Q6EURvIQkm20j7aYkWcF_75Zq0dMbmG_e8B5C1zmZCkb5nTE5Lab5CRpDCSSDoqxO0ZiQYea84iN0EeMHIVTQUpyjEVAQBWHlGL3PVEzBGdzZPnjbNd4E11mc-q0PEbsO-z4MEpNLfXK-i1gZ40PjuhVOHqe1xW_zJQaSE2w2KkbXOqP25CU6a9Um2qsfnaDXp8eXep4tlrPn-mGRmYLRlAHRtCiA51YD4y0IZrkgFbFgREO1UFobDQUHVlYaOKsa2la8EqVm2gwZ6ATdH3x3vd7axtguBbWRu-C2KnxJr5z8v-ncWq78p6QMGJRiMLg9GJjgYwy2Pd7mRO7rlXU91Cvzgbz5--rI_fZJvwGdvHZY</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Endo, Shunji</creator><creator>Dousei, Tsutomu</creator><creator>Yoshikawa, Yukinobu</creator><creator>Hatanaka, Nobutaka</creator><creator>Taniyama, Kiyomi</creator><creator>Yamauchi, Amane</creator><creator>Kamiike, Wataru</creator><creator>Nishijima, Junichi</creator><general>International College of Surgeons</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20121001</creationdate><title>Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification</title><author>Endo, Shunji ; Dousei, Tsutomu ; Yoshikawa, Yukinobu ; Hatanaka, Nobutaka ; Taniyama, Kiyomi ; Yamauchi, Amane ; Kamiike, Wataru ; Nishijima, Junichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-20b344281eb278f297e89060e2c9d3b9abbcb2482756b2876d3f68695b7bc0753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Carcinoma, Neuroendocrine - classification</topic><topic>Carcinoma, Neuroendocrine - pathology</topic><topic>Carcinoma, Neuroendocrine - surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastrectomy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neuroendocrine Tumors - classification</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Neuroendocrine Tumors - surgery</topic><topic>Neuroendocrine Tumors - therapy</topic><topic>Retrospective Studies</topic><topic>Stomach Neoplasms - classification</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - surgery</topic><topic>Stomach Neoplasms - therapy</topic><topic>Treatment Outcome</topic><topic>Upper Gastrointestinal Surgery</topic><topic>Watchful Waiting</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Endo, Shunji</creatorcontrib><creatorcontrib>Dousei, Tsutomu</creatorcontrib><creatorcontrib>Yoshikawa, Yukinobu</creatorcontrib><creatorcontrib>Hatanaka, Nobutaka</creatorcontrib><creatorcontrib>Taniyama, Kiyomi</creatorcontrib><creatorcontrib>Yamauchi, Amane</creatorcontrib><creatorcontrib>Kamiike, Wataru</creatorcontrib><creatorcontrib>Nishijima, Junichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Endo, Shunji</au><au>Dousei, Tsutomu</au><au>Yoshikawa, Yukinobu</au><au>Hatanaka, Nobutaka</au><au>Taniyama, Kiyomi</au><au>Yamauchi, Amane</au><au>Kamiike, Wataru</au><au>Nishijima, Junichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification</atitle><jtitle>International surgery</jtitle><addtitle>Int Surg</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>97</volume><issue>4</issue><spage>335</spage><epage>339</epage><pages>335-339</pages><issn>0020-8868</issn><eissn>2520-2456</eissn><abstract>In 2010, World Health Organization classified gastric neuroendocrine tumor (NET) as follows: NET grade (G) 1, NET G2, neuroendocrine carcinoma (NEC). We reviewed 22 gastric NETs that were encountered in our institutions. Nine, 6, and 4 were NET G1, G2, and NEC, respectively. We also encountered 3 NET G3. NET G1 was treated with observation in 2 patients, endoscopic mucosal resection (EMR) in 3, and gastrectomy in 4 patients. No recurrence was experienced during a median of 53 months of follow-up. All NET G2 was treated with gastrectomy. No patient experienced recurrence during a median of 25 months of follow-up. NET G3 was treated with gastrectomy. One patient died of liver metastasis 52 months after gastrectomy. For NEC, gastrectomy was performed in 3 cases and no patients died of tumor-related death. We conclude that the prognoses of NET G1 and G2 were good. We also experienced long-term survivors of NEC. An accumulation of more patients is needed for further investigation.</abstract><cop>Italy</cop><pub>International College of Surgeons</pub><pmid>23294075</pmid><doi>10.9738/cc134.1</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-8868 |
| ispartof | International surgery, 2012-10, Vol.97 (4), p.335-339 |
| issn | 0020-8868 2520-2456 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3727259 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Aged Carcinoma, Neuroendocrine - classification Carcinoma, Neuroendocrine - pathology Carcinoma, Neuroendocrine - surgery Female Follow-Up Studies Gastrectomy Humans Male Middle Aged Neoplasm Grading Neuroendocrine Tumors - classification Neuroendocrine Tumors - pathology Neuroendocrine Tumors - surgery Neuroendocrine Tumors - therapy Retrospective Studies Stomach Neoplasms - classification Stomach Neoplasms - pathology Stomach Neoplasms - surgery Stomach Neoplasms - therapy Treatment Outcome Upper Gastrointestinal Surgery Watchful Waiting World Health Organization |
| title | Gastric neuroendocrine tumors in our institutions according to the WHO 2010 classification |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T18%3A04%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20neuroendocrine%20tumors%20in%20our%20institutions%20according%20to%20the%20WHO%202010%20classification&rft.jtitle=International%20surgery&rft.au=Endo,%20Shunji&rft.date=2012-10-01&rft.volume=97&rft.issue=4&rft.spage=335&rft.epage=339&rft.pages=335-339&rft.issn=0020-8868&rft.eissn=2520-2456&rft_id=info:doi/10.9738/cc134.1&rft_dat=%3Cpubmed_cross%3E23294075%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23294075&rfr_iscdi=true |